Personalizing Care for Heart Transplant Patients
AlloMap® is a non-invasive blood test for heart transplant patients. AlloMap is the first and only non-invasive test with a rapid turnaround time that helps physicians identify the risk of acute cellular rejection in heart transplant recipients.
Since its introduction in 2005, AlloMap has helped to:
- Reduce patients’ pain, anxiety, and risk caused by biopsies through a simple, non-invasive method of blood sample collection
- Give providers accurate information on the risk of acute cellular rejection in their patients following heart transplant
AlloMap is widely used and accepted
Use of AlloMap as part of post transplantation monitoring and surveillance has become the standard of care in approximately 90% of heart transplantation programs in North America. There are now over:
insurance companies covering the test
transplant centers utilizing AlloMap
years clinical use and experience
The FDA’s AlloMap Decision Summary is available here.
Included in ISHLT Guidelines
AlloMap has received the highest grade evidence-basis of invasive or non-invasive rejection monitoring technologies. This level of recommendation is equal to or higher than the recommendation level for any methodology for monitoring for rejection, including endomyocardial biopsy, which has been the traditional standard for 40 years. Read the full guidelines here.
Outcomes data published in peer-reviewed publications
Read more about our clinical data in the New England Journal of Medicine, Transplantation, Circulation and other journals.